Oxford University study finds Ozempic (semaglutide) may reduce dementia risk by 48% and lower cognitive decline and nicotine use.

A diabetes treatment drug, Ozempic, may reduce the risk of dementia by up to 48%, according to an Oxford University study. The study, published in the Lancet's eClinicalMedicine journal, found that Ozempic, or semaglutide, was not associated with a higher risk of any neurological or psychiatric conditions, and patients taking Ozempic had lower rates of cognitive decline and nicotine use. The findings suggest that treatment with semaglutide and similar drugs may be associated with a lower risk of dementia and can help reduce nicotine addiction.

July 11, 2024
13 Articles